Autonomix Medical, Inc. (NASDAQ:AMIX) Stock Short Interest Report for October

Autonomix Medical, Inc. (NASDAQ:AMIX) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 58,986 shares, an increase of 119.9% from the September 30th total of 26,830 shares. Approximately 6.4% of the company’s stock are sold short. Based on an average daily volume of 282,590 shares, the short-interest ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Autonomix Medical in a research report on Monday. Wall Street Zen raised shares of Autonomix Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, October 3rd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Autonomix Medical has an average rating of “Hold” and an average target price of $42.00.

Autonomix Medical Stock Performance

AMIX stock traded up $0.05 on Friday, reaching $2.09. The company had a trading volume of 11,002 shares, compared to its average volume of 1,407,755. Autonomix Medical has a 1 year low of $2.04 and a 1 year high of $32.55. The company’s fifty day moving average is $3.89 and its 200 day moving average is $6.86. The company has a market cap of $2.03 million, a P/E ratio of -0.05 and a beta of -0.96.

Autonomix Medical (NASDAQ:AMIX) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, topping the consensus estimate of ($6.40) by $1.38. On average, sell-side analysts predict that Autonomix Medical will post -20.17 earnings per share for the current year.

About Autonomix Medical

Autonomix Medical, Inc is a medical device company developing catheter-based technologies for the detection and treatment of conditions involving the peripheral nervous system. The company’s platform is designed to identify neural signals in real time, with the goal of helping physicians locate and selectively treat targeted nerves during minimally invasive procedures.

Autonomix’s lead development program is focused on pain associated with pancreatic cancer. Its technology is intended to support targeted nerve ablation, potentially offering an alternative approach for managing pain while reducing the need for more extensive procedures.